Sign In
Buy HALO
$69.82
+3.54 (+5.34%)
At Close: Jun 03, 2026
Halozyme weighing buyout of drugmaker Evotec, Bloomberg News reports
04:09pm, Thursday, 14'th Nov 2024
German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics , Bloomberg News reported on Thursday.
Halozyme: Looking For More Growth Following Record Q3 Earnings
12:24pm, Tuesday, 05'th Nov 2024
Halozyme's Q3 earnings exceeded expectations, with a $1.27 EPS and 34% YoY revenue growth, driven by ENHANZE tech and strong partnerships with J&J and Roche. The partnership model using ENHANZE tech m
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
10:45am, Monday, 04'th Nov 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Halozyme Announces Record Earnings, Guidance
11:42am, Friday, 01'st Nov 2024
Halozyme Therapeutics, Inc. (HALO) shares are up after record revenue growth, improved guidance, and expansion plans.
HALO Beats Q3 Earnings & Sales Estimates, Raises '24 View, Stock Up
10:50am, Friday, 01'st Nov 2024
Halozyme reports better-than-expected third-quarter 2024 results. The company raises revenue guidance for 2024.
Halozyme Therapeutics, Inc. (HALO) Q3 2024 Earnings Call Transcript
07:39pm, Thursday, 31'st Oct 2024
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Helen Torley - President, Chief Executive Officer Nicole LaBrosse - Chief F
Halozyme Therapeutics (HALO) Reports Q3 Earnings: What Key Metrics Have to Say
06:31pm, Thursday, 31'st Oct 2024
Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare
Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates
06:20pm, Thursday, 31'st Oct 2024
Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $0.75 per share a year ago.
HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS
04:01pm, Thursday, 31'st Oct 2024
Total Revenue Increased 34% YOY to $290 million and Royalty Revenue Increased 36% YOY to $155 million Net Income Increased 67% YOY to $137 million and Adjusted EBITDA Increased 60% YOY to $184 millio
HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE
06:30am, Thursday, 24'th Oct 2024
Company Projects No Impact on U.S. or European Royalty Revenues from DARZALEX FASPRO® and SC through 2032 Reiterates 2024 Royalty Revenue Guidance of $520-555 million and Expectations to Generate > $
Halozyme to Report Third Quarter 2024 Financial and Operating Results
04:30pm, Wednesday, 23'rd Oct 2024
SAN DIEGO , Oct. 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2024 financial and operating results on Thursday, O
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
10:45am, Thursday, 17'th Oct 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Wells Fargo Downgrades Halozyme Therapeutics (HALO) Due to Limited Upside
04:12am, Tuesday, 08'th Oct 2024
Wells Fargo has downgraded its rating for Halozyme Therapeutics (HALO, Financial), a U.S. biotechnology company, from "Overweight" to "Equal Weight," with a target price set at $62, indicating limited
Why Halozyme Therapeutics (HALO) Could Beat Earnings Estimates Again
01:15pm, Monday, 07'th Oct 2024
Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
09:51am, Monday, 07'th Oct 2024
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
